Obsidian (OBX) CEO Jagasia Madan Receives Option Grant for 37,653 Shares

What Happened
Jagasia Madan, CEO of Obsidian Therapeutics (OBX), was granted a derivative award covering 37,653 shares on 2026-08-03. The grant price reported is $0.00 (no cash paid at grant) and the award is an option-like instrument — not an exercised sale or open-market purchase. This is a compensation award rather than a buy or sell by the insider.

Key Details

• Transaction date: 2026-08-03; Form filed 2026-08-05 (filed timely within the typical 2-business-day window).
• Transaction type/code: Award/Grant (A) of a derivative instrument covering 37,653 shares; price reported $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The underlying shares vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the issuer's annual meeting following the grant date, subject to continued service.
• Not an exercise or sale: No immediate cash proceeds or share sales were reported.

Context
This grant is a typical equity compensation action for an executive. The award will only convert to exercisable options (and potentially shares after exercise) if vesting conditions are met; until then it does not represent freely tradable shares or realized value. Such grants are common and reflect company compensation practices rather than an independent purchase or sale signal.